American Clinical Research Services Announces Rebranding to Elixia
16 Julio 2024 - 5:30AM
Business Wire
American Clinical Research Services (ACRS), a leader in complex
clinical research, is proud to announce its rebranding to Elixia,
signifying the company’s expanded vision and capabilities in the
clinical research and patient recruitment sectors. Elixia is a
portfolio company of Latticework Capital Management.
This transition to Elixia signifies more than a name change,
embodying the company’s commitment to drug development and
healthcare delivery. Elixia combines the robust capabilities of
premier clinical research sites with a leading patient recruitment
engine, enabling it to support clinical trials with efficiency and
precision. The name Elixia was chosen to capture the essence of the
company’s mission: to accelerate the development of life-changing
therapies and improve patient outcomes worldwide.
“Rebranding to Elixia represents the unification of our diverse
strengths under a shared vision,” said Dustin Owen, CEO of Elixia.
“Our integrated approach and expanded reach uniquely position us to
address the complexities of modern drug development. With Elixia,
we are poised to make a profound impact on the healthcare
landscape, driving innovations that bring new treatments to
patients faster and more effectively than ever before.”
Established in 2022 through the acquisition of Catalina Research
Institute, a leader in therapeutically focused clinical research,
ACRS has positioned itself as a significant player in the industry.
Building on this foundation, ACRS strengthened its services in
2023, acquiring CSSi and Patient Advertising Guru, both prominent
companies specializing in patient recruitment. The culmination of
these strategic acquisitions is the recent addition of Elixia,
whose name will now be adopted for the entire organization. The
company remains committed to its partners, patients and
stakeholders as it embarks on this exciting new chapter.
About Elixia
Elixia is an industry-leading clinical research entity, linking
a vast network of multi-site clinical research facilities with a
global patient recruitment operation. With sites in California,
Florida, Massachusetts, Missouri, Michigan, and Texas, Elixia
conducts Phase I-IV studies, addressing complex conditions in
metabolic health, nephrology, neuroscience, and infectious
diseases. Elixia is renowned globally for its technological
prowess, which enhances efficiency in patient acquisition and
offers critical health outcome data that provides invaluable
insights to sponsors worldwide. For more information, please visit
elixiahealth.com.
About Latticework Capital Management (LCM)
Headquartered in Dallas, TX, Latticework is a growth oriented
private equity firm focused exclusively on making control equity
investments in the healthcare industry. LCM has completed more than
130 transactions across a diverse array of healthcare subsectors
and currently has more than $550 million in assets under
management. LCM leverages its more than 100 combined years of
healthcare and investing experience, as well as its network of
industry executives, to help companies scale and realize their full
long-term value. For more information, please visit
latticeworkcapital.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240716441996/en/
Jeremy Milner BackBay Communications (401) 862-9422
jeremy.milner@backbaycommunications.com